April 26th 2024
The clearance of the IND application for RAG-01 will initiate the launch of clinical trials in the US.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Intravesical chemotherapy device shows promise in muscle-invasive bladder cancer
April 14th 2023"Our preliminary clinical trial found that TAR-200 was generally safe, well tolerated, and had beneficial effects on bladder cancer outcomes in a group of patients with limited treatment options," said Mark Tyson, MD, MPH.
Expert: Work needed to validate changes in diagnostic work-up for upper tract urothelial carcinoma
April 12th 2023“I think clinicians can really take away that we have more work to be done in this space of evaluating patients with microhematuria, specifically when it comes to looking at assessments of upper tract urothelial carcinoma or renal cell carcinoma,” says Jacob Taylor, MD, MPH.
Study identifies potential biomarkers for response to immunotherapy in urothelial carcinoma
April 12th 2023The investigators identified several genetic factors, including ARID1A mutation, that correlated with survival outcomes in patients with advanced urothelial carcinoma treated with immune checkpoint blockade.
How findings on the impact of bladder cancer treatment affect clinical decision-making
April 10th 2023"Understanding work productivity and activity impairment in the context of the treatment decisions are vital, not just for the provider who has to counsel on treatment benefits and risks, but also to the patient who's making the ultimate decision," says Angela Smith, MD, MS.
Dr. Sridhar on long-term follow-up from the JAVELIN Bladder 100 trial
March 14th 2023Regardless of the type of chemotherapy regimen received, there was a benefit with the use of frontline avelumab maintenance in patients with locally advanced or metastatic urothelial carcinoma, explains Srikala S. Sridhar, MD.
FDA fast tracks treatment for immune checkpoint inhibitor–resistant urothelial carcinoma
March 13th 2023“There is an urgent need for new treatment options for [patients with] urothelial carcinoma, many of whom find themselves out of options after progressing on immune checkpoint inhibitors," said Sergio Santillana, MD.
Dr. Grivas discusses real-world study of frontline avelumab maintenance in urothelial carcinoma
March 10th 2023Avelumab is approved by the FDA as a maintenance therapy for patients with locally advanced/metastatic urothelial carcinoma that has not progressed with first-line, platinum-based chemotherapy.
Developing personalized quality-of-life measures for patients undergoing radical cystectomy
March 2nd 2023“What we'd like to try to do in our research is see if we can begin to develop a tool that is more personalized for patients, that can provide a more useful approach to quality of life,” says Bernard H. Bochner, MD, FACS.
Exploratory analysis shows no OS benefit with atezolizumab monotherapy in advanced urothelial cancer
February 18th 2023An exploratory analysis of the IMvigor130 study failed to show an improvement in overall survival with atezolizumab, compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.
Clinical complete response may guide eligibility for cystectomy in MIBC
February 17th 2023In the the phase 2 HCRN GU 16-257 trial, 33 patients with muscle-invasive bladder cancer were eligible to forego cystectomy and continue 240-mg maintenance nivolumab monotherapy every 2 weeks for 8 cycles followed by surveillance.